Personalized care for older adults with lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study compares two ways of managing care for older adults with a type of blood cancer called lymphoma. One group gets standard care, the other gets a plan adjusted to their overall health and frailty, which might help them tolerate treatment better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 70 years old or older.
- You have been diagnosed with diffuse large B-cell lymphoma (DLBCL) or a certain type of follicular lymphoma (grade IIIB).
- Your doctor has checked your health and said you are 'unfit' or 'frail' for standard care.
- You are eligible to receive standard first-line treatment (chemotherapy plus immunotherapy) with the goal of curing the lymphoma.
- You are able to understand the study and willing to follow its procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for people with a type of lymphoma called diffuse large B cell lymphoma, especially if you are older or not healthy enough for standard full-dose chemotherapy. The treatment includes two immunotherapy drugs (epcoritamab and polatuzumab) plus a reduced-intensity chemotherapy regimen (mini-CHP). The goal is to see if this combination is safe and effective for people who may not tolerate stronger treatments.
This trial tests a combination of four medications (pomalidomide, rituximab, orelabrutinib, and polatuzumab vedotin) for newly diagnosed, elderly patients with diffuse large B-cell lymphoma (DLBCL) who cannot tolerate standard treatments. It aims to see if this combination is effective and safe for older adults.
This trial studies a specific treatment plan to see how well it works for adults with newly diagnosed non-Hodgkin lymphoma that has a high amount of disease. It may help by aiming to control lymphoma more effectively, especially when it is widespread.
This study tests a combination of three newer targeted drugs for older adults (70+) who have just been diagnosed with diffuse large B-cell lymphoma and have not yet received any treatment. The goal is to see if this drug combo can control the lymphoma effectively while being manageable for older patients.
This trial tests a combination of three drugs (pola, Rituxan, and lenalidomide) for older adults (70+) with a common type of lymphoma (DLBCL) who are not well enough for standard chemotherapy. The goal is to see if this gentler treatment works well for patients who are less fit.
This trial tests a combination of two drugs, rituximab and CC-99282, as a first treatment for older adults with diffuse large b-cell lymphoma who are too frail for standard chemotherapy. The goal is to see if this gentler approach can effectively control the disease while being easier to tolerate.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.